全文获取类型
收费全文 | 164篇 |
免费 | 14篇 |
专业分类
耳鼻咽喉 | 3篇 |
基础医学 | 6篇 |
口腔科学 | 4篇 |
临床医学 | 22篇 |
内科学 | 65篇 |
神经病学 | 11篇 |
外科学 | 3篇 |
预防医学 | 3篇 |
药学 | 2篇 |
肿瘤学 | 59篇 |
出版年
2023年 | 2篇 |
2022年 | 7篇 |
2021年 | 9篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 2篇 |
2014年 | 5篇 |
2013年 | 6篇 |
2012年 | 12篇 |
2011年 | 13篇 |
2010年 | 2篇 |
2009年 | 2篇 |
2008年 | 8篇 |
2007年 | 13篇 |
2006年 | 9篇 |
2005年 | 8篇 |
2004年 | 8篇 |
2003年 | 4篇 |
2002年 | 4篇 |
2001年 | 10篇 |
2000年 | 2篇 |
1999年 | 7篇 |
1998年 | 1篇 |
1997年 | 5篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 7篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1983年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有178条查询结果,搜索用时 15 毫秒
91.
Shigeki Ito Masako Iwanaga Kisato Nosaka Yoshitaka Imaizumi Kenji Ishitsuka Masahiro Amano Atae Utsunomiya Yoshiki Tokura Toshiki Watanabe Kaoru Uchimaru Kunihiro Tsukasaki Collaborative Investigators 《Cancer science》2021,112(10):4346-4354
Adult T-cell leukemia-lymphoma (ATL) is a T-cell malignancy that is endemic to Japan. In this latest nationwide study of ATL, we collected the data from 4 nationwide registries of patients diagnosed in 2012-2013; the Hematology Blood Disease, the Skin Cancer Society, the Hospital-Based Cancer Registries, and information from the hospitals that participated in the Japanese nationwide survey of ATL in 2010-2011. In the present study, 2614 patients with ATL were diagnosed based on the registries, and 117 departments registered 1042 patients. Among these patients, 984 were eligible for analysis. The median age at diagnosis was 69 y. A larger proportion of patients with ATL older than 70 y was diagnosed with the lymphoma subtype, and more than half of the patients with ATL in the metropolitan areas were born in the human T-cell leukemia virus type I (HTLV-1)-endemic areas of Kyushu/Okinawa, which are almost identical to the findings in our 2010-2011 study. Additionally, we identified that patients with ATL migrated from the endemic areas for HTLV-1 to the non-endemic metropolitan areas. The present study was able to reduce the burden of searching each hospital and to update the clinico-epidemiological characteristics of a large number of patients with ATL in Japan, suggesting the usefulness and feasibility of the novel data collection method. The establishment of a more sophisticated database management system for ATL is necessary for future continuous surveys. 相似文献
92.
Kenichi M Masanobu M Takehiko K Shoko T Akira F Katsushige A Takashi H Yoshiyuki O Shigeru K 《The Journal of laboratory and clinical medicine》2004,144(2):69-77
Plasmin is an important factor in the degradation of extracellular matrix. In the study reported here we examined the expression of plasminogen-activator inhibitor-1 (PAI-1), urokinase-type plasminogen activator (uPA), and uPA receptor (uPAR), as well as the relevance of such expression to the production of type IV collagen, a major component of extracellular matrix, in the renal tissue of rats with streptozotocin-induced diabetes. Because angiotensin II is involved in the synthesis of PAI-1 and uPA, we also examined the effect of benazepril, an angiotensin-converting-enzyme inhibitor, on the expression of PAI-1, uPA, and uPAR messenger RNAs (mRNAs) and type IV collagen protein. Rats with streptozocin-induced diabetes-some untreated and some treated with 30 mg/L benazepril-and nondiabetic control rats were sacrificed at 4, 12, or 24 weeks after induction of diabetes. We examined the expression of PAI-1, uPA, and uPAR mRNAs through the use of in situ hybridization and that of type IV collagen by means of immunohistochemical methods. In control rats, we detected weak signals for PAI-1, uPA, and uPAR mRNAs in glomeruli. Diabetic rats exhibited high levels of expression of PAI-1, uPA, and uPAR mRNAs and type IV collagen protein, mainly in mesangial cells. These mRNAs were synthesized in various renal cells (epithelial, mesangial, and endothelial cells and Bowman's capsule). Benazepril inhibited increases in all 3 mRNAs, especially in the mesangium; reduced type IV collagen expression; and attenuated mesangial expansion. Our results indicated that altered expression of PAI-1, uPA, and uPAR in diabetic nephropathy was associated with mesangial expansion and that the beneficial effects of ACE-I may be at least associated with such expression. 相似文献
93.
Kazunori Ohnishi Ken Ohmachi Kiyoshi Ando Kazuhito Yamamoto Tatsuya Ito Mitsune Tanimoto Kaneyuki Ohbayashi Kazuma Ohyashiki Kunihiro Tsukasaki Kensuke Naito Takayo Suzuki Takaaki Ono Koichi Miyamura Yoshitoyo Kagami Tomohiro Kinoshita Tomomitsu Hotta Michinori Ogura 《Journal of Clinical and Experimental Hematopathology》2021,61(3):162
The optimal combined chemotherapy regimen with rituximab has yet to be established for elderly patients with advanced-stage indolent B-cell lymphoma (B-NHL). A multicenter study was performed to evaluate the efficacy and toxicity of R-THP-COP therapy in elderly patients (aged 70–79 years) with newly diagnosed advanced-stage indolent B-NHL using the complete response rate (%CR) as the primary endpoint. Patients with newly diagnosed, clinical stage III/IV, indolent B-NHL, aged 70–79 years, with a performance status of 0–2 were eligible for this study. R-THP-COP consists of 375 mg/m2 of rituximab, 50 mg/m2 of pirarubicin, 750 mg/m2 of cyclophosphamide, 1.4 mg/m2 of vincristine, and 100 mg/day of oral prednisolone for 5 days. This study was discontinued due to poor accrual after the enrollment of 18 patients, although the planned sample size was 40 patients. The numbers of patients with follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, and mantle cell lymphoma were 16, 1, and 1, respectively. The median age was 73 (range, 70 to 79) years. The %CR including unconfirmed CR was 45% (95% confidence interval: 25-66%) and the overall response rate was 72%. The estimated 5-year overall survival and progression-free survival rates were 55% and 28%, respectively. The major toxicity observed was grade 4 neutropenia (94%). Grade 4 non-hematological toxicities were not observed and no patients developed grade 3/4 cardiac toxicities. This phase II study provides useful information regarding the efficacy and toxicity of R-THP-COP therapy for patients aged 70 years or older with newly diagnosed, advanced-stage, indolent B-NHL, although the sample size was small. 相似文献
94.
Katsunori Yanagihara Yuko Kitagawa Masao Tomonaga Kunihiro Tsukasaki Shigeru Kohno Masafumi Seki Hisashi Sugimoto Takeshi Shimazu Osamu Tasaki Asako Matsushima Yasuo Ikeda Shinichiro Okamoto Naoki Aikawa Shingo Hori Hideaki Obara Akitoshi Ishizaka Naoki Hasegawa Junzo Takeda Shimeru Kamihira Kazuyuki Sugahara Seishi Asari Mitsuru Murata Yoshio Kobayashi Hiroyuki Ginba Yoshinobu Sumiyama Masaki Kitajima 《Critical care (London, England)》2010,14(4):1-9
Introduction
Altered pharmacokinetics (PK) in critically ill patients can result in insufficient serum β-lactam concentrations when standard dosages are administered. Previous studies on β-lactam PK have generally excluded the most severely ill patients, or were conducted during the steady-state period of treatment. The aim of our study was to determine whether the first dose of piperacillin-tazobactam, ceftazidime, cefepime, and meropenem would result in adequate serum drug concentrations in patients with severe sepsis and septic shock.Methods
Open, prospective, multicenter study in four Belgian intensive care units. All consecutive patients with a diagnosis of severe sepsis or septic shock, in whom treatment with the study drugs was indicated, were included. Serum concentrations of the antibiotics were determined by high-pressure liquid chromatography (HPLC) before and 1, 1.5, 4.5 and 6 or 8 hours after administration.Results
80 patients were treated with piperacillin-tazobactam (n = 27), ceftazidime (n = 18), cefepime (n = 19) or meropenem (n = 16). Serum concentrations remained above 4 times the minimal inhibitory concentration (T > 4 × MIC), corresponding to the clinical breakpoint for Pseudomonas aeruginosa defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), for 57% of the dosage interval for meropenem (target MIC = 8 μg/mL), 45% for ceftazidime (MIC = 32 μg/mL), 34% for cefepime (MIC = 32 μg/mL), and 33% for piperacillin-tazobactam (MIC = 64 μg/mL). The number of patients who attained the target PK profile was 12/16 for meropenem (75%), 5/18 for ceftazidime (28%), 3/19 (16%) for cefepime, and 12/27 (44%) for piperacillin-tazobactam.Conclusions
Serum concentrations of the antibiotic after the first dose were acceptable only for meropenem. Standard dosage regimens for piperacillin-tazobactam, ceftazidime and cefepime may, therefore, be insufficient to empirically cover less susceptible pathogens in the early phase of severe sepsis and septic shock. 相似文献95.
Dai Maruyama Shinsuke Iida Ryunosuke Machida Shigeru Kusumoto Noriko Fukuhara Nobuhiko Yamauchi Kana Miyazaki Makoto Yoshimitsu Junya Kuroda Norifumi Tsukamoto Hideki Tsujimura Kensuke Usuki Takahiro Yamauchi Takahiko Utsumi Ishikazu Mizuno Yasushi Takamatsu Yasuyuki Nagata Shuichi Ota Eiichi Ohtsuka Ichiro Hanamura Yasuhiro Suzuki Shinichiro Yoshida Satoshi Yamasaki Youko Suehiro Yutaro Kamiyama Suguru Fukuhara Kunihiro Tsukasaki Hirokazu Nagai 《Cancer science》2022,113(9):3267
96.
Kazuhiro Itoh Hiroko Shigemi Keiichi Kinoshita Hikaru Tsukasaki Shin Imamura Koji Morinaga Nobuyuki Yoshio Takashi Nakayama Hitoshi Inoue Takanori Ueda Takahiro Yamauchi Hiromichi Iwasaki 《Internal medicine (Tokyo, Japan)》2022,61(20):3037
Introduction Invasive fungal infections have been attracting attention as significant fatal complications in patients with febrile neutropenia (FN) who undergo intensive chemotherapy or hematopoietic stem cell transplantation to treat hematological malignancies. Although clinical trials are already underway in other countries, evidence supporting the use of caspofungin (CAS) in FN patients in Japan is still insufficient. Methods A retrospective study of patients treated with CAS for FN associated with hematological diseases between April 2015 and March 2018 was conducted to determine the treatment efficacy and safety. The study was conducted as a multicenter collaboration, and the data of 52 patients who met all of the inclusion criteria were analyzed. A five-composite-endpoint method was used, and the treatment was judged to be effective when all five endpoints (defervescence during neutropenia; no breakthrough fungal infections; resolution of baseline fungal infections; a survival for seven days or more after the completion of therapy; and no discontinuation of therapy due to side effects or invalidity) were met. Results The efficacy rate was 53.8% (28/52), which is close to the average reported efficacy rate. Adverse events included liver dysfunction and electrolyte abnormalities, but no renal dysfunction or serious events were seen. Conclusion These results suggest that the use of CAS in FN patients with hematological diseases is effective and well-tolerated, and we believe that the use of CAS could become a significant treatment in Japan. 相似文献
97.
Shin Lee Kei Fujita Tetsuji Morishita Eiju Negoro Kana Oiwa Hikaru Tsukasaki Osamu Yamamura Takanori Ueda Takahiro Yamauchi 《British journal of haematology》2021,192(1):100-109
Reflecting the increasing risk in elderly patients with diffuse large B cell lymphoma (DLBCL), prognostic predictors other than the International Prognostic Index have attracted more attention. This study presents the first analysis of the prognostic utility of the Geriatric Nutritional Risk Index (GNRI) in combination with the Charlson Comorbidity Index (CCI) for overall survival (OS) in elderly DLBCL patients. A multicentre retrospective was conducted on a cohort of 451 patients (≥65 years). The GNRI and CCI were independent predictors in a multivariate Cox proportional hazard model. There was a nonlinear correlation between the GNRI and OS in a Cox model with restricted cubic spline. Multivariate receiver operating characteristic curves showed a significant improvement in prediction accuracy when the GNRI was added to CCI. Adding the GNRI to CCI yielded a significant category‐free net reclassification improvement (0·556; 95% CI: 0·378–0·736, P < 0·001) and integrated discrimination improvement (0·094; 95% CI: 0·067–0·122, P < 0·001). The decision curve analysis demonstrated the clinical net benefit associated with the adoption of the GNRI. The GNRI was not only a predictor of OS but also remarkably improved the prognosis prediction accuracy when incorporated with the CCI, having the ability to stratify the prognosis of elderly DLBCL patients. 相似文献
98.
99.
Itonaga H Fukushima T Taguchi J Imanishi D Imaizumi Y Hata T Tsukasaki K Miyazaki Y 《[Rinshō ketsueki] The Japanese journal of clinical hematology》2011,52(12):1870-1875
Granular lymphocyte proliferative disorder (GLPD) is often concomitant with a malignant tumor. We report a patient who developed acute monoblastic leukemia (AMoL) following GLPD. An 82-year-old Japanese man was admitted to our hospital for anemia in December 2006. The patient was diagnosed as having GLPD. In May 2007, the lymphadenopathy developed and the blasts in peripheral blood started to increase. The monoclonal rearrangement of T-cell receptor genes was not detected on Southern blot analysis. Surface marker analysis revealed that the blasts were positive for CD13 and CD64. The level of lysozyme in serum and urine were increased. Based on these findings, he was diagnosed with AMoL. The immunohistochemistry of the bone marrow clot specimen in the diagnosis of GLPD revealed the concomitant presence of a few small clusters of CD34+ cells. This finding suggests that the granular lymphocytes responded to the early stage of AMoL. We should monitor carefully the development of acute myeloid leukemia in newly diagnosed GLPD patients. 相似文献
100.
Matsuo E Miyazaki Y Tsutsumi C Inoue Y Yamasaki R Hata T Fukushima T Tsushima H Imanishi D Imaizumi Y Iwanaga M Sakai M Ando K Sawayama Y Ogawa D Kawaguchi Y Nagai K Tsukasaki K Ikeda S Moriuchi Y Yoshida S Honda M Taguchi J Onimaru Y Tsuchiya T Tawara M Atogami S Yamamura M Soda H Yoshida Y Matsuo Y Nonaka H Joh T Takasaki Y Kawasaki C Momita S Jinnai I Kuriyama K Tomonaga M 《International journal of hematology》2007,85(2):132-139
To evaluate the efficacy of imatinib in a practical setting, we registered 43 patients with newly diagnosed chronic myelogenous
leukemia (CML) (group I) and 56 patients with previously diagnosed CML (group II) at 11 hematology centers in Nagasaki prefecture,
Japan, from December 2001 to July 2005 and analyzed the molecular responses. Cytopenia, fluid retention, and skin rash were
major adverse events, along with elevation in creatine phosphokinase levels. With a follow-up of approximately 3.5 years,
imatinib treatment led to 88.7% overall survival (OS) and 85.2% progression-free survival (PFS) rates for group I, and 79.8%
OS and 76.6% PFS rates for group II; the rates were not significantly different despite a lower average imatinib dose in group
II.The rates of complete cytogenetic response at 30 months and major molecular response at 24 months were 86.1% and 62.5%,
respectively, in group I, and 77.9% and 58.3% in group II; the rates were not significantly different. As has been reported
by other groups, these results demonstrate that imatinib treatment can provide excellent clinical and molecular effects for
not only newly diagnosed but also previously treated CML patients in practical settings that cover a wider variety of patients
than clinical trials. 相似文献